On September 27, 2023 Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, reported the acceptance of two abstracts (related to TAC-001 and TAC-003) at the SITC (Free SITC Whitepaper) 38th Annual Meeting in San Diego, CA, from November 3-5, 2023 (Press release, Tallac Therapeutics, SEP 27, 2023, View Source [SID1234635459])b.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Additionally, Tallac announced that President and CEO, Hong Wan and Chief Business Officer, Curtis Hecht will participate and host investor meetings at the Truist Securities BioPharma Symposium on November 8-9, 2023 in New York, NY.
Details of the SITC (Free SITC Whitepaper) poster presentations are as follows:
Title: INCLINE-101: Preliminary Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAC-001 (TLR9 agonist conjugated to a CD22 mAb) in Patients with Advanced or Metastatic Solid Tumors
Abstract/Poster #: 743
Session Date: Friday, Nov. 3, 2023
Title: TAC-003, a TLR9 agonist antibody conjugate for targeted immunotherapy of Nectin-4 expressing tumors
Abstract/Poster #: 1121
Session Date: Friday, Nov. 3, 2023
Both abstracts will be available for viewing on October 31, 2023 at 9:00 am EDT on the Journal for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (JITC) website.
About TAC-001 (CD22 TRAAC)
TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC) comprised of a potent toll-like receptor 9 agonist (T-CpG) conjugated to an antibody against CD22, a receptor restricted to B cells, including tumor-infiltrating B cells. TAC-001 is designed to systemically deliver T-CpG to B cells by binding to CD22, leading to internalization of TAC-001, TLR9 signaling, B cell activation and a cascade of immune reactions. Preclinical studies demonstrate that the innate and adaptive immune responses triggered by TAC-001 leads to potent anti-tumor activity. TAC-001 is being developed for the potential treatment of solid tumors and is currently in a Phase 1/2 Study in cancer patients (NCT05399654)
About TAC-003 (anti-Nectin-4 TRAAC)
TAC-003 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC) comprised of a T-CpG conjugated to a novel Nectin-4-targeting antibody for systemic administration and TME delivery of a potent TLR9 agonist. Nectin-4 is a cancer associated antigen over-expressed in many solid tumor types with limited expression in normal tissues. Additionally, Nectin-4 over-expression correlates with poor prognosis. Preclinical data demonstrate that TAC-003 triggers TLR9 signaling, induces myeloid and dendritic cell activation, phagocytosis, cytokine production and lymphocyte activation, resulting in potent anti-tumor efficacy.